Online remote behavioural intervention for tics in 9- to 17-year-olds: the ORBIT RCT with embedded process and economic evaluation.

ADOLESCENT BEHAVIOUR THERAPY CHILD DIGITAL HEALTH EXPOSURE RESPONSE PREVENTION HEALTH ECONOMIC EVALUATION ONLINE PROCESS EVALUATION RANDOMISED CONTROLLED TRIAL TIC DISORDER TICS TOURETTE SYNDROME

Journal

Health technology assessment (Winchester, England)
ISSN: 2046-4924
Titre abrégé: Health Technol Assess
Pays: England
ID NLM: 9706284

Informations de publication

Date de publication:
Oct 2023
Historique:
medline: 6 11 2023
pubmed: 4 11 2023
entrez: 4 11 2023
Statut: ppublish

Résumé

Behavioural therapy for tics is difficult to access, and little is known about its effectiveness when delivered online. To investigate the clinical and cost-effectiveness of an online-delivered, therapist- and parent-supported therapy for young people with tic disorders. Single-blind, parallel-group, randomised controlled trial, with 3-month (primary end point) and 6-month post-randomisation follow-up. Participants were individually randomised (1 : 1), using on online system, with block randomisations, stratified by site. Naturalistic follow-up was conducted at 12 and 18 months post-randomisation when participants were free to access non-trial interventions. A subset of participants participated in a process evaluation. Two hospitals (London and Nottingham) in England also accepting referrals from patient identification centres and online self-referrals. Children aged 9-17 years (1) with Tourette syndrome or chronic tic disorder, (2) with a Yale Global Tic Severity Scale-total tic severity score of 15 or more (or > 10 with only motor or vocal tics) and (3) having not received behavioural therapy for tics in the past 12 months or started/stopped medication for tics within the past 2 months. Either 10 weeks of online, remotely delivered, therapist-supported exposure and response prevention therapy (intervention group) or online psychoeducation (control). Primary outcome: Yale Global Tic Severity Scale-total tic severity score 3 months post-randomisation; analysis done in all randomised patients for whom data were available. Secondary outcomes included low mood, anxiety, treatment satisfaction and health resource use. Quality-adjusted life-years are derived from parent-completed quality-of-life measures. All trial staff, statisticians and the chief investigator were masked to group allocation. Two hundred and twenty-four participants were randomised to the intervention ( Two serious, unrelated adverse events occurred in the control group. We cannot separate the effects of digital online delivery and the therapy itself. The sample was predominately white and British, limiting generalisability. The design did not compare to face-to-face services. Online, therapist-supported behavioural therapy for young people with tic disorders is clinically and cost-effective in reducing tics, with durable benefits extending up to 18 months. Future work should compare online to face-to-face therapy and explore how to embed the intervention in clinical practice. This trial is registered as ISRCTN70758207; ClinicalTrials.gov (NCT03483493). The trial is now complete. This project was funded by the National Institute for Health and Care Research (NIHR) Health and Technology Assessment programme (project number 16/19/02) and will be published in full in It can be difficult for children and young people with tics to access therapy. This is because there are not enough trained tic therapists. Online remote behavioural intervention for tics was a clinical trial to see whether an online platform that delivered two different types of interventions could help tics. One intervention focused on techniques to control tics; this type of therapy is called exposure and response prevention. The other intervention was psychoeducation, where participants learned about the nature of tics but not how to control them. The online remote behavioural intervention for tics interventions also involved help from a therapist and support from a parent. Participants were aged 9–17 years with Tourette syndrome/chronic tic disorder and were recruited from 16 clinics, two study sites (Nottingham and London) or via online self-referral. All individuals who were eligible for the online remote behavioural intervention for tics trial were randomised in a 50/50 split by researchers who were unaware of which treatment was being given. Participants received either 10 weeks of online exposure and response prevention or 10 weeks of online psychoeducation. A total of 224 children and young people participated: 112 allocated to exposure and response prevention and 112 to psychoeducation. Tics decreased more in the exposure and response prevention group (16% reduction) than in the psychoeducation group (6% reduction) 3 months after treatment. This difference is considered a clinically important difference in tic reduction. The treatment continued to have a positive effect on tic symptoms at 6, 12 and 18 months, showing that the effects are durable. This was achieved with minimal therapist involvement. The cost of online exposure and response prevention to treat young people with tics within this study was less when compared to the cost of face-to-face therapy. The results show that exposure and response prevention is an effective behavioural therapy for tics in this specific patient group. Delivering exposure and response prevention online with minimal therapist contact can be a successful and cost-effective treatment to improve access to behavioural therapy.

Sections du résumé

Background UNASSIGNED
Behavioural therapy for tics is difficult to access, and little is known about its effectiveness when delivered online.
Objective UNASSIGNED
To investigate the clinical and cost-effectiveness of an online-delivered, therapist- and parent-supported therapy for young people with tic disorders.
Design UNASSIGNED
Single-blind, parallel-group, randomised controlled trial, with 3-month (primary end point) and 6-month post-randomisation follow-up. Participants were individually randomised (1 : 1), using on online system, with block randomisations, stratified by site. Naturalistic follow-up was conducted at 12 and 18 months post-randomisation when participants were free to access non-trial interventions. A subset of participants participated in a process evaluation.
Setting UNASSIGNED
Two hospitals (London and Nottingham) in England also accepting referrals from patient identification centres and online self-referrals.
Participants UNASSIGNED
Children aged 9-17 years (1) with Tourette syndrome or chronic tic disorder, (2) with a Yale Global Tic Severity Scale-total tic severity score of 15 or more (or > 10 with only motor or vocal tics) and (3) having not received behavioural therapy for tics in the past 12 months or started/stopped medication for tics within the past 2 months.
Interventions UNASSIGNED
Either 10 weeks of online, remotely delivered, therapist-supported exposure and response prevention therapy (intervention group) or online psychoeducation (control).
Outcome UNASSIGNED
Primary outcome: Yale Global Tic Severity Scale-total tic severity score 3 months post-randomisation; analysis done in all randomised patients for whom data were available. Secondary outcomes included low mood, anxiety, treatment satisfaction and health resource use. Quality-adjusted life-years are derived from parent-completed quality-of-life measures. All trial staff, statisticians and the chief investigator were masked to group allocation.
Results UNASSIGNED
Two hundred and twenty-four participants were randomised to the intervention (
Harms UNASSIGNED
Two serious, unrelated adverse events occurred in the control group.
Limitations UNASSIGNED
We cannot separate the effects of digital online delivery and the therapy itself. The sample was predominately white and British, limiting generalisability. The design did not compare to face-to-face services.
Conclusion UNASSIGNED
Online, therapist-supported behavioural therapy for young people with tic disorders is clinically and cost-effective in reducing tics, with durable benefits extending up to 18 months.
Future work UNASSIGNED
Future work should compare online to face-to-face therapy and explore how to embed the intervention in clinical practice.
Trial registration UNASSIGNED
This trial is registered as ISRCTN70758207; ClinicalTrials.gov (NCT03483493). The trial is now complete.
Funding UNASSIGNED
This project was funded by the National Institute for Health and Care Research (NIHR) Health and Technology Assessment programme (project number 16/19/02) and will be published in full in
It can be difficult for children and young people with tics to access therapy. This is because there are not enough trained tic therapists. Online remote behavioural intervention for tics was a clinical trial to see whether an online platform that delivered two different types of interventions could help tics. One intervention focused on techniques to control tics; this type of therapy is called exposure and response prevention. The other intervention was psychoeducation, where participants learned about the nature of tics but not how to control them. The online remote behavioural intervention for tics interventions also involved help from a therapist and support from a parent. Participants were aged 9–17 years with Tourette syndrome/chronic tic disorder and were recruited from 16 clinics, two study sites (Nottingham and London) or via online self-referral. All individuals who were eligible for the online remote behavioural intervention for tics trial were randomised in a 50/50 split by researchers who were unaware of which treatment was being given. Participants received either 10 weeks of online exposure and response prevention or 10 weeks of online psychoeducation. A total of 224 children and young people participated: 112 allocated to exposure and response prevention and 112 to psychoeducation. Tics decreased more in the exposure and response prevention group (16% reduction) than in the psychoeducation group (6% reduction) 3 months after treatment. This difference is considered a clinically important difference in tic reduction. The treatment continued to have a positive effect on tic symptoms at 6, 12 and 18 months, showing that the effects are durable. This was achieved with minimal therapist involvement. The cost of online exposure and response prevention to treat young people with tics within this study was less when compared to the cost of face-to-face therapy. The results show that exposure and response prevention is an effective behavioural therapy for tics in this specific patient group. Delivering exposure and response prevention online with minimal therapist contact can be a successful and cost-effective treatment to improve access to behavioural therapy.

Autres résumés

Type: plain-language-summary (eng)
It can be difficult for children and young people with tics to access therapy. This is because there are not enough trained tic therapists. Online remote behavioural intervention for tics was a clinical trial to see whether an online platform that delivered two different types of interventions could help tics. One intervention focused on techniques to control tics; this type of therapy is called exposure and response prevention. The other intervention was psychoeducation, where participants learned about the nature of tics but not how to control them. The online remote behavioural intervention for tics interventions also involved help from a therapist and support from a parent. Participants were aged 9–17 years with Tourette syndrome/chronic tic disorder and were recruited from 16 clinics, two study sites (Nottingham and London) or via online self-referral. All individuals who were eligible for the online remote behavioural intervention for tics trial were randomised in a 50/50 split by researchers who were unaware of which treatment was being given. Participants received either 10 weeks of online exposure and response prevention or 10 weeks of online psychoeducation. A total of 224 children and young people participated: 112 allocated to exposure and response prevention and 112 to psychoeducation. Tics decreased more in the exposure and response prevention group (16% reduction) than in the psychoeducation group (6% reduction) 3 months after treatment. This difference is considered a clinically important difference in tic reduction. The treatment continued to have a positive effect on tic symptoms at 6, 12 and 18 months, showing that the effects are durable. This was achieved with minimal therapist involvement. The cost of online exposure and response prevention to treat young people with tics within this study was less when compared to the cost of face-to-face therapy. The results show that exposure and response prevention is an effective behavioural therapy for tics in this specific patient group. Delivering exposure and response prevention online with minimal therapist contact can be a successful and cost-effective treatment to improve access to behavioural therapy.

Identifiants

pubmed: 37924247
doi: 10.3310/CPMS3211
pmc: PMC10641713
doi:

Banques de données

ClinicalTrials.gov
['NCT03483493']

Types de publication

Randomized Controlled Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-120

Références

Behav Res Ther. 2004 May;42(5):501-11
pubmed: 15033497
Ophthalmic Physiol Opt. 2014 Sep;34(5):502-8
pubmed: 24697967
J Child Psychol Psychiatry. 2000 Jul;41(5):645-55
pubmed: 10946756
Contemp Clin Trials. 2013 Nov;36(2):414-20
pubmed: 24001701
Clin Child Fam Psychol Rev. 2015 Jun;18(2):133-50
pubmed: 25726421
Dev Med Child Neurol. 2009 Jun;51(6):468-72
pubmed: 19018838
World Psychiatry. 2014 Oct;13(3):288-95
pubmed: 25273302
Behav Res Ther. 2012 Sep;50(9):565-70
pubmed: 22743661
Br J Psychiatry. 2007 Dec;191:521-7
pubmed: 18055956
J Psychosom Res. 2009 Dec;67(6):497-501
pubmed: 19913654
Int J Psychiatry Clin Pract. 2018 Nov;22(4):262-267
pubmed: 29325470
Implement Sci. 2009 May 21;4:29
pubmed: 19460163
BMC Psychiatry. 2015 Mar 11;15:46
pubmed: 25879205
Behav Modif. 2008 Mar;32(2):215-27
pubmed: 18285507
J Child Psychol Psychiatry. 2017 Apr;58(4):474-503
pubmed: 27943285
Prog Neuropsychopharmacol Biol Psychiatry. 2016 Oct 3;70:227-36
pubmed: 26875502
J Clin Med. 2022 Jan 04;11(1):
pubmed: 35011989
Behav Res Ther. 2016 Jan;76:47-56
pubmed: 26649465
Clin Child Fam Psychol Rev. 2019 Jun;22(2):147-171
pubmed: 30229343
Int J Behav Nutr Phys Act. 2016 Jan 19;13:7
pubmed: 26785637
Appl Health Econ Health Policy. 2011 May 1;9(3):157-69
pubmed: 21506622
BMC Med Res Methodol. 2013 Sep 18;13:117
pubmed: 24047204
Qual Health Res. 2005 Nov;15(9):1277-88
pubmed: 16204405
BMJ. 2008 Sep 29;337:a1655
pubmed: 18824488
J Clin Epidemiol. 2013 Aug;66(8):874-82
pubmed: 23810026
BMJ Open. 2019 Jun 5;9(6):e026820
pubmed: 31171550
BMJ Open. 2017 Jan 23;7(1):e014844
pubmed: 28115336
BJPsych Open. 2019 Aug 14;5(5):e74
pubmed: 31409430
Eur Child Adolesc Psychiatry. 2022 Feb;31(2):275-287
pubmed: 33231786
JAMA. 2010 May 19;303(19):1929-37
pubmed: 20483969
Behav Res Ther. 2016 May;80:43-50
pubmed: 27037483
Behav Ther. 2017 Nov;48(6):834-846
pubmed: 29029679
Child Adolesc Ment Health. 2020 May;25(2):120-122
pubmed: 32307846
JAMA Psychiatry. 2021 Jul 1;78(7):705-713
pubmed: 33978699
J Child Psychol Psychiatry. 1999 Jul;40(5):791-9
pubmed: 10433412
J Child Psychol Psychiatry. 2016 Sep;57(9):988-1004
pubmed: 27132945
Community Ment Health J. 2013 Feb;49(1):110-20
pubmed: 22052430
Trials. 2020 Jan 2;21(1):6
pubmed: 31898510
Eur Child Adolesc Psychiatry. 2011 Apr;20(4):173-96
pubmed: 21445724
BMJ. 2015 Mar 19;350:h1258
pubmed: 25791983
J Med Internet Res. 2004 Nov 10;6(4):e40
pubmed: 15631964
Soc Psychiatry Psychiatr Epidemiol. 2017 Nov;52(11):1405-1413
pubmed: 28849245
Behav Res Ther. 1998 May;36(5):545-66
pubmed: 9648330
J Pers Soc Psychol. 1986 Dec;51(6):1173-82
pubmed: 3806354
Implement Sci. 2007 Nov 30;2:40
pubmed: 18053122
Neurology. 2019 May 7;92(19):896-906
pubmed: 31061208
Expert Rev Pharmacoecon Outcomes Res. 2012 Dec;12(6):745-64
pubmed: 23252357
Health Technol Assess. 2016 Jan;20(4):1-450, vii-viii
pubmed: 26786936
Eur Psychiatry. 2011 Sep;26(6):370-4
pubmed: 20427154
J Behav Ther Exp Psychiatry. 1983 Sep;14(3):197-201
pubmed: 6358263
Eur Child Adolesc Psychiatry. 2011 Apr;20(4):197-207
pubmed: 21445725
Psychiatry Res. 2013 Dec 15;210(2):675-7
pubmed: 23850206
Health Qual Life Outcomes. 2015 Feb 18;13:22
pubmed: 25890377
Internet Interv. 2020 Jan 27;20:100308
pubmed: 32082991
JAMA. 2021 May 11;325(18):1863-1873
pubmed: 33974020
Behav Res Ther. 2013 Jan;51(1):24-30
pubmed: 23168328
J Med Internet Res. 2021 Jun 21;23(6):e25470
pubmed: 34152270
Soc Sci Med. 2012 Dec;75(12):2299-306
pubmed: 22989491
J Med Internet Res. 2011 Jan 06;13(1):e2
pubmed: 21212045
PLoS One. 2014 Jun 20;9(6):e100773
pubmed: 24949622
J Am Acad Child Adolesc Psychiatry. 2001 Nov;40(11):1337-45
pubmed: 11699809
Mol Autism. 2014 Jan 10;5(1):1
pubmed: 24410847
Behav Res Ther. 2015 Apr;67:1-18
pubmed: 25727678
BMJ Open. 2019 Feb 15;9(2):e024685
pubmed: 30772854
Arch Dis Child. 2001 May;84(5):404-9
pubmed: 11316683
PLoS One. 2021 Sep 16;16(9):e0257270
pubmed: 34529705
BMJ. 2004 Jun 26;328(7455):1561-3
pubmed: 15217878
Neurology. 2017 Mar 14;88(11):1029-1036
pubmed: 28202705
J Neurol. 2011 Feb;258(2):291-301
pubmed: 20859745
Milbank Q. 2010 Dec;88(4):500-59
pubmed: 21166868
J Child Psychol Psychiatry. 2006 Sep;47(9):927-34
pubmed: 16930387
Eur Child Adolesc Psychiatry. 2021 Mar;30(3):461-473
pubmed: 32436035
Arch Gen Psychiatry. 1983 Nov;40(11):1228-31
pubmed: 6639293
BMC Med. 2010 Oct 20;8:63
pubmed: 20961442
Br J Psychiatry. 2006 Jun;188:541-6
pubmed: 16738344
J Child Neurol. 2017 Jan;32(1):76-83
pubmed: 27686095
Clin Child Fam Psychol Rev. 1999 Dec;2(4):199-254
pubmed: 11225935
Trials. 2013 Jan 12;14:15
pubmed: 23311722
Br J Psychiatry. 2013 Dec;203(6):436-44
pubmed: 23969483
Lancet Psychiatry. 2021 Oct;8(10):871-882
pubmed: 34480868
Cogn Behav Ther. 2013;42(4):303-14
pubmed: 24245708
PLoS One. 2016 Oct 6;11(10):e0164311
pubmed: 27711249
BMC Med Res Methodol. 2019 Mar 15;19(1):59
pubmed: 30876403
Health Technol Assess. 2015 Feb;19(14):1-503, v-vi
pubmed: 25692211
Eur J Paediatr Neurol. 2012 Nov;16(6):605-12
pubmed: 22381812
Clin Child Fam Psychol Rev. 2005 Jun;8(2):149-66
pubmed: 15984084
JAMA Psychiatry. 2015 Apr;72(4):325-33
pubmed: 25671412
Child Care Health Dev. 2013 Sep;39(5):617-27
pubmed: 23461278
J Clin Child Adolesc Psychol. 2007 Apr-Jun;36(2):217-27
pubmed: 17484694
J Am Acad Child Adolesc Psychiatry. 2022 Jun;61(6):764-771
pubmed: 34508805
Behav Res Ther. 2006 Sep;44(9):1287-300
pubmed: 16313883
Clin Psychol Rev. 2016 Dec;50:1-10
pubmed: 27668988
Qual Saf Health Care. 2003 Feb;12(1):40-6
pubmed: 12571344
Annu Rev Public Health. 2009;30:273-92
pubmed: 19296777
BMJ. 2000 Oct 28;321(7268):1047-50
pubmed: 11053174
Psychol Methods. 2002 Mar;7(1):83-104
pubmed: 11928892
Implement Sci. 2016 Mar 22;11:40
pubmed: 27001107
Br J Psychiatry. 1999 Jan;174:56-62
pubmed: 10211152
J Telemed Telecare. 2016 Apr;22(3):153-62
pubmed: 26169350
NPJ Digit Med. 2020 Jun 15;3:85
pubmed: 32566763
Health Educ Res. 2008 Dec;23(6):976-86
pubmed: 18559401
Arch Gen Psychiatry. 2003 Aug;60(8):837-44
pubmed: 12912767
Behav Res Ther. 2014 Jul;58:10-23
pubmed: 24864005
Eur Child Adolesc Psychiatry. 2019 Jan;28(1):57-68
pubmed: 29956034
J Am Acad Child Adolesc Psychiatry. 1989 Jul;28(4):566-73
pubmed: 2768151
J Autism Dev Disord. 2012 Dec;42(12):2702-17
pubmed: 22527708
Child Care Health Dev. 2009 Jul;35(4):496-504
pubmed: 19638024
J Med Internet Res. 2020 Jul 31;22(7):e16924
pubmed: 32735227
Eur Child Adolesc Psychiatry. 2022 Mar;31(3):403-423
pubmed: 34313861
Int J Methods Psychiatr Res. 2004;13(3):141-51
pubmed: 15297898
J Child Psychol Psychiatry. 2023 Jun;64(6):941-951
pubmed: 36649686
Arch Gen Psychiatry. 2012 Aug;69(8):795-803
pubmed: 22868933
J Adv Nurs. 2020 Mar;76(3):903-915
pubmed: 31782167
Expert Rev Neurother. 2012 Jul;12(7):861-9; quiz 870
pubmed: 22853793
Implement Sci. 2010 Sep 03;5:67
pubmed: 20815872
Front Psychiatry. 2018 Mar 27;9:100
pubmed: 29636706
BMJ. 2010 Sep 17;341:c4587
pubmed: 20851841
J Med Internet Res. 2019 Nov 1;21(11):e13478
pubmed: 31682573
BMJ Open. 2019 Jan 3;9(1):e027583
pubmed: 30610027
Med Decis Making. 2003 Jul-Aug;23(4):341-50
pubmed: 12926584
PLoS One. 2011;6(6):e21274
pubmed: 21712998
Mov Disord. 2009 May 15;24(7):1070-3
pubmed: 19306279
Behav Ther. 2020 Jul;51(4):659-669
pubmed: 32586437

Auteurs

Chris Hollis (C)

NIHR MindTech MedTech Co-operative, Institute of Mental Health, School of Medicine, University of Nottingham, Nottingham, UK.
NIHR Nottingham Biomedical Research Centre, Institute of Mental Health, University of Nottingham, Nottingham, UK.
Mental Health and Clinical Neurosciences, School of Medicine, University of Nottingham, Queen's Medical Centre, Nottingham, UK.
Department of Child and Adolescent Psychiatry, Nottinghamshire Healthcare NHS Foundation Trust, South Block Level E, Queen's Medical Centre, Nottingham, UK.

Charlotte L Hall (CL)

NIHR MindTech MedTech Co-operative, Institute of Mental Health, School of Medicine, University of Nottingham, Nottingham, UK.
NIHR Nottingham Biomedical Research Centre, Institute of Mental Health, University of Nottingham, Nottingham, UK.
Mental Health and Clinical Neurosciences, School of Medicine, University of Nottingham, Queen's Medical Centre, Nottingham, UK.

Kareem Khan (K)

NIHR MindTech MedTech Co-operative, Institute of Mental Health, School of Medicine, University of Nottingham, Nottingham, UK.
Mental Health and Clinical Neurosciences, School of Medicine, University of Nottingham, Queen's Medical Centre, Nottingham, UK.

Marie Le Novere (M)

Research Department of Primary Care and Population Health and Priment CTU, University College London, London, UK.

Louise Marston (L)

Research Department of Primary Care and Population Health and Priment CTU, University College London, London, UK.

Rebecca Jones (R)

Division of Psychiatry and Priment CTU, University College London, London, UK.

Rachael Hunter (R)

Research Department of Primary Care and Population Health and Priment CTU, University College London, London, UK.

Beverley J Brown (BJ)

NIHR MindTech MedTech Co-operative, Institute of Mental Health, School of Medicine, University of Nottingham, Nottingham, UK.

Charlotte Sanderson (C)

UCL Great Ormond Street Institute of Child Health (ICH), London, UK/Great Ormond Street Hospital for Children NHS Trust, London, UK.
Psychological and Mental Health Services, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.

Per Andrén (P)

Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, and Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden.

Sophie D Bennett (SD)

UCL Great Ormond Street Institute of Child Health (ICH), London, UK/Great Ormond Street Hospital for Children NHS Trust, London, UK.
Psychological and Mental Health Services, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.

Liam R Chamberlain (LR)

NIHR MindTech MedTech Co-operative, Institute of Mental Health, School of Medicine, University of Nottingham, Nottingham, UK.

E Bethan Davies (EB)

NIHR MindTech MedTech Co-operative, Institute of Mental Health, School of Medicine, University of Nottingham, Nottingham, UK.
Mental Health and Clinical Neurosciences, School of Medicine, University of Nottingham, Queen's Medical Centre, Nottingham, UK.

Amber Evans (A)

UCL Great Ormond Street Institute of Child Health (ICH), London, UK/Great Ormond Street Hospital for Children NHS Trust, London, UK.
Psychological and Mental Health Services, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.

Natalia Kouzoupi (N)

UCL Great Ormond Street Institute of Child Health (ICH), London, UK/Great Ormond Street Hospital for Children NHS Trust, London, UK.
Psychological and Mental Health Services, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.

Caitlin McKenzie (C)

NIHR MindTech MedTech Co-operative, Institute of Mental Health, School of Medicine, University of Nottingham, Nottingham, UK.

Isobel Heyman (I)

UCL Great Ormond Street Institute of Child Health (ICH), London, UK/Great Ormond Street Hospital for Children NHS Trust, London, UK.
Psychological and Mental Health Services, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.

Joseph Kilgariff (J)

Department of Child and Adolescent Psychiatry, Nottinghamshire Healthcare NHS Foundation Trust, South Block Level E, Queen's Medical Centre, Nottingham, UK.

Cristine Glazebrook (C)

NIHR MindTech MedTech Co-operative, Institute of Mental Health, School of Medicine, University of Nottingham, Nottingham, UK.
Mental Health and Clinical Neurosciences, School of Medicine, University of Nottingham, Queen's Medical Centre, Nottingham, UK.

David Mataix-Cols (D)

Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, and Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden.

Eva Serlachius (E)

Department of Clinical Sciences, Faculty of Medicine, Lund University, Lund, Sweden.

Elizabeth Murray (E)

Research Department of Primary Care and Population Health and Priment CTU, University College London, London, UK.

Tara Murphy (T)

UCL Great Ormond Street Institute of Child Health (ICH), London, UK/Great Ormond Street Hospital for Children NHS Trust, London, UK.
Psychological and Mental Health Services, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH